ReviewJournal of cancer research and clinical oncology2024
Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors.
Review in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 54 citations in OpenAlex.
- Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients.European journal of clinical investigation · 2026Trial
- Advances in miR‑200c regulation of apoptosis, pyroptosis and autophagy in disease (Review).Molecular medicine reports · 2026Review
- Angiogenic Doping: Plausible Yet Difficult to Detect.Sports medicine (Auckland, N.Z.) · 2026Review
- Beyond Lymphovascular Invasion: Site-Dependent Patterns of Lymphatic, Venous and Perineural Involvement in Laryngo-Hypopharyngeal Carcinoma.Medical sciences (Basel, Switzerland) · 2026Article
- [MBD1 knockdown inhibits proliferation, migration and angiogenesis of human umbilical vein endothelial cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Impact of Iron Speciation on the Cytotoxicity and Gene Expression Profile of BiofortifiedMolecules (Basel, Switzerland) · 2026Article
- Tissue Homogenate VEGF Levels in Malignant Salivary Gland Tumors vs. Controls: An Exploratory Pilot Study.Journal of clinical medicine · 2026Article
- Review
- Antitumor Activity of Sodium Selenite, Palbociclib, and Disulfiram Against Osteosarcoma and Rhabdomyosarcoma Cell Lines.Drug development research · 2026Article
- The pyrazolo[3,4-d]pyrimidine derivative CLM24 has an antineoplastic effect in aggressive dedifferentiated thyroid cancer in vitro.Endocrine · 2026Article
- Characterization of complex renal cysts in hereditary leiomyomatosis and renal cell cancerUsing magnetic resonance based qualitative features.Abdominal radiology (New York) · 2026Article
- The predictive diagnostic value of combined serum detection of CXCL12, VEGF, and CA125 for endometriosis.Medicine · 2026Article
- Breast cancer: taxonomy, distribution analysis, risk factors, predictive biomarkers, and modern treatment method.Apoptosis : an international journal on programmed cell death · 2026Review
- Gecko protein F2 inhibits tumor angiogenesis by suppressing the VEGF/MAPK/ERK signaling pathway.Medical oncology (Northwood, London, England) · 2026Article
- ALKBH5 promotes gastric cancer angiogenesis by stabilizing LncRNA PVT1 and VEGFA RNAs via m6A demethylation.Molecular and cellular biochemistry · 2026Article
- The Heterogeneity and Function of Stromal Cells in the Tumor Microenvironment.Research (Washington, D.C.) · 2026Review
- Circ_0075829 affects POU5F1B expression through sponging miR-576-3p to promote growth, invasion, and angiogenesis of colon cancer cells.American journal of cancer research · 2026Article
- Nomogram integrating BRAF V600E, serum biomarkers, and ultrasound features for malignancy risk stratification in C-TIRADS category 3 and 4 thyroid nodules.Frontiers in medicine · 2026Article
- The Anti-lung Cancer Mechanism of Qingzao Jiufei Decoction was Studied based on Network Pharmacology, Molecular Docking, and Experimental Verification.Combinatorial chemistry & high throughput screening · 2026Article
- Migrasome-related long non-coding RNAs orchestrate immune microenvironment and serve as a novel prognostic model in clear cell renal cell carcinoma.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor A (VEGF-A), a highly conserved dimeric glycoprotein, is a key regulatory gene and a marker molecule of angiogenesis. The upregulation of VEGF-A facilitates the process of tumor vascularization, thereby fostering the initiation and progression of malignant neoplasms. Many genes can adjust the angiogenesis of tumors by changing the expression of VEGF-A. In addition, VEGF-A also exhibits immune regulatory properties, which directly or indirectly suppresses the antitumor activity of immune cells. The emergence of VEGF-A-targeted therapy alone or in rational combinations has revolutionized the treatment of various cancers. This review discusses how diverse mechanisms in various tumors regulate VEGF-A expression to promote tumor angiogenesis and the role of VEGF-A in tumor immune microenvironment. The application of drugs targeting VEGF-A in tumor therapy is also summarized including antibody molecule drugs and traditional Chinese medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.